It is indeed surprising that Dodd and Esposito passed on the bid. I can only figure that they decided to cut their losses, rather than gamble on summoning enough support to finish the FDA process, and try to commercialize.
Bottom line? Marshall gave away twenty years of his life, with blood, sweat and tears, to get the tech through the EPA, then got slammed unexpectedly with the FDA challenge.
Could he have handled things in a more efficient way, and gotten to the same point faster? Very possibly.
But the one area in which he wasn't deficient was his passion to bring AS to the healthcare sector and save lives.
I just don't think that Dodd and Esposito have the same passion, and this translated into a much more cautious approach to the uncertainties of a bankruptcy situation.
From a pure business perspective, maybe they're right. But there are times when passion overcomes the more "sensible" approach.
For our sake, I hope that this will be one of those times.
